PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor. MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010. RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %. CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.
PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor. MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010. RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %. CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.
Authors: Martin G Mack; Ralf Straub; Katrin Eichler; Oliver Söllner; Thomas Lehnert; Thomas J Vogl Journal: Radiology Date: 2004-09-30 Impact factor: 11.105
Authors: Tobias F Jakobs; Ralf-Thorsten Hoffmann; Angelika Schrader; Hans Joachim Stemmler; Christoph Trumm; Andreas Lubienski; Ravi Murthy; Thomas K Helmberger; Maximilian F Reiser Journal: Cardiovasc Intervent Radiol Date: 2008-06-25 Impact factor: 2.740
Authors: C T Sofocleous; R G Nascimento; M Gonen; M Theodoulou; A M Covey; L A Brody; S M Solomon; R Thornton; Y Fong; G I Getrajdman; K T Brown Journal: AJR Am J Roentgenol Date: 2007-10 Impact factor: 3.959
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: Olga Golubnitschaja; Kristina Yeghiazaryan; Helena Stricker; Daniela Trog; Hans H Schild; Leonard Berliner Journal: BMC Cancer Date: 2016-06-08 Impact factor: 4.430